Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 48.6% | -28.3% | 183% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 77.7% | 77.4% | 79.8% | 89% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | $0 | -$0 |
| % Margin | 12.7% | -8.2% | 28.5% | -156.8% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | $0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 7.4% | -6.8% | 30.3% | -156.8% |
| EPS | 0.68 | -0.44 | 2.88 | -7.1 |
| % Growth | 254.5% | -115.3% | 140.6% | – |
| EPS Diluted | 0.51 | -0.44 | 2.17 | -7.1 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | $0 | -$0 |
| % Margin | 14.3% | -5.6% | 29.2% | -156.4% |